Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 44 Breast Neoplasms 42 Lung Neoplasms 27 Carcinoma, Non-Small-Cell Lung 21 Colorectal Neoplasms 19 Uterine Cervical Neoplasms 13 Prostatic Neoplasms 13 Ovarian Neoplasms 11 Head and Neck Neoplasms 11 Carcinoma, Hepatocellular 11 Pancreatic Neoplasms 10 Melanoma 10 Brain Neoplasms 9 Sarcoma 7 Neoplastic Cells, Circulating 7 Myelodysplastic Syndromes 7 Glioma 7 Esophageal Neoplasms 7 Endometrial Neoplasms 7 Multiple Myeloma 6 Gastrointestinal Neoplasms 6 Disease 6 Carcinoma, Renal Cell 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 5 Leukemia, Myeloid, Acute 5 Colonic Neoplasms 5 Uveal Melanoma 4 Skin Neoplasms 4 Neoplasm, Residual 4

Interventions

pembrolizumab 2 darolutamide 2 relatlimab 1 olaparib 1 gedatolisib 1 enfortumab vedotin 1 Surveys and Questionnaires 1 Radiation Dose Hypofractionation 1 Pluvicto 1 Nivolumab 1 Mitomycin 1 Gemcitabine 1 Fluorouracil 1 Cisplatin 1 CP protocol 1 Blood Specimen Collection 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Male Urogenital Diseases × Blood Specimen Collection × 1 year × Clear all

NCT06659926 2025-07-08

The Radium-select Study

The Netherlands Cancer Institute

Phase NA Recruiting

Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡